Challenger

Challenger
CME and Preparatory ProductsProgramsWeb ProductsReviewsTech SupportFrequently Asked Questions


Quick Quiz Newsletter
Compliments of Challenger Corporation

Click image to enlarge




Med-Challenger EM Career
The Gold Standard Reference and Review for Emergency Physicians


For more information on Challenger's boards preparation, clinical review, and other electronic resources for physicians, visit www.chall.com, or call a Challenger Sales Representative at
1-800-676-0822, ext. 4400.

Try Our Products!
Click Here for a Free Demonstration
.

Issue: March 1, 2008
Case:
Eye Inflammation and Infection
Taken from
Med-Challenger EM Career
All Products | Challenger Corporation
Click Here for a Free Product Demonstration.

Question:

A mother brings in her child for evaluation of a bilateral purulent eye discharge, photophobia, and congestion (see image). On exam, you palpate enlarged pre-auricular lymph nodes. Which of the following statements is CORRECT?

 
  1. The patient's congestion is most likely due to an upper respiratory infection with respiratory syncytial virus (RSV).
  2. The patient is most likely suffering from vernal conjunctivitis.
  3. Fluorescein staining might reveal corneal punctate lesions.
  4. Lymphadenopathy supports a diagnosis of bacterial conjunctivitis.

Answer:
Click here for the answer and clinical remediation.

    Win a $500 Educational Grant!
    Write a Question and Answer for ANY Challenger Educational Course. If our Physicians Advisory Board selects YOUR question at their semiannual meeting, you'll receive a $500 educational grant.

    All submissions become the intellectual property of Challenger Corporation but you'll receive author credit for the Question and Answer in our next release. VIEW DETAILS HERE.

    View past newsletters here.


    If you received this newsletter from a friend, Click here to receive your own Quick Quiz Newsletter.

    Compliments of Challenger Corporation
    5100 Poplar Avenue, Ste. 1410
    Memphis, TN 38137


    Copyright (C) Challenger Corporation. All rights reserved.